Known targets — ChEMBL curated mechanism
MMP1MMP13MMP7MMP8polrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Betulin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 4/20 | 0.98 |
| ▸ | TOP2A | P11388 | 2/20 | 0.98 |
| ▸ | USP2 | O75604 | 2/20 | 0.98 |
| ▸ | LMNA | P02545 | 2/20 | 0.98 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.98 |
| ▸ | NT5E | P21589 | 2/20 | 0.98 |
| ▸ | RELA | Q04206 | 1/20 | 0.98 |
| ▸ | CES2 | O00748 | 2/20 | 0.72 |
| ▸ | CES1 | P23141 | 2/20 | 0.72 |
| ▸ | RORC | P51449 | 4/20 | 0.69 |
| ▸ | ALB | P02768 | 3/20 | 0.69 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.69 |
| ▸ | POLB | P06746 | 1/20 | 0.69 |
| ▸ | GLI1 | P08151 | 1/20 | 0.69 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.69 |
| ▸ | DPP4 | P27487 | 1/20 | 0.69 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.69 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.69 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.69 |
| ▸ | SLC10A1 | Q14973 | 2/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Betulin SCHEMBL8656184 | 0.99 | PTPN1 (1.00) | PTPN1TOP2AUSP2LMNAHIF1A | |
| Betulin SCHEMBL13908773 | 0.99 | PTPN1 (1.00) | PTPN1TOP2AUSP2LMNAHIF1A | |
| Betulin SCHEMBL20776118 | 0.99 | PTPN1 (1.00) | PTPN1TOP2AUSP2LMNAHIF1A | |
| Betulin SCHEMBL15074885 | 0.99 | PTPN1 (1.00) | PTPN1TOP2AUSP2LMNAHIF1A | |
| Betulin SCHEMBL2733535 | 0.99 | PTPN1 (1.00) | PTPN1TOP2AUSP2LMNAHIF1A | |
| Betulin SCHEMBL9905923 | 0.99 | PTPN1 (1.00) | PTPN1TOP2AUSP2LMNAHIF1A | |
| Betulin SCHEMBL7215658 | 0.99 | PTPN1 (1.00) | PTPN1TOP2AUSP2LMNAHIF1A | |
| Betulin SCHEMBL7749571 | 0.99 | PTPN1 (1.00) | PTPN1TOP2AUSP2LMNAHIF1A | |
| Betulin SCHEMBL13806589 | 0.99 | PTPN1 (1.00) | PTPN1TOP2AUSP2LMNAHIF1A | |
| Betulin SCHEMBL19452465 | 0.99 | PTPN1 (1.00) | PTPN1TOP2AUSP2LMNAHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210299118-A1 | Coordinated Metabolic Reprogramming in Response to Productive Viral Infections | ST. JUDE CHILDREN'S RESEARCH HOSPITAL | 2021-09-30 | — | — | US | disclosed |
| US-11083725-B2 | Coordinated metabolic reprogramming in response to productive viral infections | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2021-08-10 | — | — | US | disclosed |
| US-20170304293-A1 | COORDINATED METABOLIC REPROGRAMMING IN RESPONSE TO PRODUCTIVE VIRAL INFECTIONS | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2017-10-26 | — | — | US | disclosed |
| US-7851462-B2 | Methods and compositions for inhibiting tumor growth | NOVELIX PHARMACEUTICALS, INC. (US) | 2010-12-14 | — | — | US | disclosed |
| EP-1594885-B8 | MEDICAMENT FOR INHIBITING TUMOUR GROWTH | NOVELIX PHARMACEUTICALS INC (US) | 2009-03-25 | — | — | EP | disclosed |
| EP-1594885-B1 | MEDICAMENT FOR INHIBITING TUMOUR GROWTH | NOVELIX PHARMACEUTICALS INC (US) | 2009-01-07 | — | — | EP | disclosed |
| US-20080214516-A1 | METHODS AND COMPOSITIONS FOR INHIBITING TUMOR GROWTH | NOVELIX PHARMACEUTICALS, INC. (US) | 2008-09-04 | — | — | US | disclosed |
| US-7312205-B2 | Methods and compositions for inhibiting tumor growth | NOVELIX PHARMACEUTICALS, INC. (US) | 2007-12-25 | — | — | US | disclosed |
| US-20060194774-A1 | Medicament for inhibiting tumour growth | NOVELIX PHARMACEUTICALS, INC. (US) | 2006-08-31 | — | — | US | disclosed |
| EP-1594885-A1 | MEDICAMENT FOR INHIBITING TUMOUR GROWTH | Novelix Pharmaceuticals, Inc. (US) | 2005-11-16 | — | — | EP | disclosed |
| WO-2004072092-A1 | MEDICAMENT FOR INHIBITING TUMOUR GROWTH | NOVELIX PHARMACEUTICALS, INC. (US) | 2004-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210299118-A1 | Coordinated Metabolic Reprogramming in Response to Productive Viral Infections | MAVS, ATF4, PC | PTPN1 3976/4885TOP2A 3142/4885USP2 2352/4885 |
| US-20080214516-A1 | METHODS AND COMPOSITIONS FOR INHIBITING TUMOR GROWTH | BET1, MKI67, PGGT1B | PTPN1 3867/4885TOP2A 1068/4885USP2 4006/4885 |
| US-20060194774-A1 | Medicament for inhibiting tumour growth | MKI67, BET1, NFATC1 | PTPN1 3983/4885TOP2A 1891/4885USP2 3556/4885 |
| US-20170304293-A1 | COORDINATED METABOLIC REPROGRAMMING IN RESPONSE TO PRODUCTIVE VIRAL INFECTIONS | MAVS, ATF4, PC | PTPN1 3976/4885TOP2A 3142/4885USP2 2352/4885 |
| US-11083725-B2 | Coordinated metabolic reprogramming in response to productive viral infections | MAVS, ATF4, PC | PTPN1 3976/4885TOP2A 3142/4885USP2 2352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.